THOUGHT LEADER SESSIONS

MONDAY 27TH JUNE 2022- 17:00 - 18:00 CET

Thought Leader Session

1 Together4RD - Multistakeholder initiative to unlock
ERN collaboration with
industry

Chaired by Sheela Upadhyaya, National Institute For Health And Clinical Excellence Thought Leader Session 2

Rare Diseases International-Preparing the foundations of a Global Rare Disease Network

Chaired by Matt Bolz-Johnson, EURORDIS

Thought Leader Session 3

Rare Diseases (RD) Partnership (Horizon Europe)-Ambition, Vision and Mission

Chaired by Daria Julkowska, European Programme on Rare Diseases

Session Descriptions

Thought Leader Session 1

Together4RD – Multi-stakeholder initiative to unlock ERN collaboration with industry

Chaired by Sheela Upadhyaya, National Institute For Health And Clinical Excellence

27 June 2022 | 17:00-18:00

Together for Rare Diseases is a multi-stakeholder initiative aimed at supporting European Reference Networks (ERNs) to collaborate with stakeholders to pursue opportunities that will address unmet medical needs of people living with rare diseases. The aim is to unlock opportunities for partnerships, particularly with the pharmaceutical industry.

This Thought Leader Session will introduce the work of the multi-stakeholder initiative, Together for Rare Diseases, and offer perspectives from ERN coordinators, patient representatives, industry and policymakers involved in the project on the need to support ERN collaboration with industry in areas that will address the 95% unmet medical needs of people living with rare diseases. The objective of the session will be to outline the steps needed to unlock collaboration and make a call to action for support from the conference attendees.

Agenda: Timing CEST

17:00: Welcome & introduction to Together4RD

Sheela Upadhyaya, Chair of the Together4RD Steering Group

17:15: Keynote and Call to Action

Ondrej Knotek (Renew Europe, Czechia), MEP Champion of Together4RD

17:20: Panel discussion: Unlocking ERN collaboration with the pharmaceutical industry to accelerate research for the 95% unmet medical need in rare diseases

Andrzej Rys, DG SANTE, European Commission Hélène Dollfus, Chair, ERN-EYE Coordinator

Roseline Favresse, Research Policy & Initiatives Director, EURORDIS

Toon Digneffe, Head Public Affairs & Public Policy - Europe & Canada at Takeda; Member of EUCOPE Executive Board

Discussion moderated by Sheela Upadhyaya, Chair of the Together4RD Steering Group

17:50: Opportunity for audience Q&A Closing remarks and next steps

18:00: Close

Thought Leader Session 2

RDI – Preparing the foundations of a Global Rare Disease Network

Chaired by Matt Bolz Johnson, EURORDIS

27 June 2022 | 17:00-18:00

Rare Diseases International is collaborating with the World Health Organization to develop a global 'network of networks' that will connect existing collaborations of expert centres and patient organisations. The Global Network for Rare Diseases will support the implementation of Universal Health Coverage, targeting vulnerable and marginalised populations and progressively providing coverage, improving patient access to and coordination of high quality healthcare.

An international Panel of Experts was established in 2019, with leaders from over 100 countries, to codefine healthcare needs, co-design the Network model, and co-create an operational framework for a pilot Global Network for Rare Diseases. Existing clinical networks in rare diseases are leading the development of new models of care for rare diseases. In the EU, the European Reference Networks (ERN) have demonstrated proof of concept for "networked care" that facilitate sharing of experience across the network. National networks have been established in China, France, Japan and now in the USA. Rare Disease "lighthouse" centres that are connected under an existing collaboration or networks will be the flagships for this model of global networked care, and when scaled up and connected under a global network, will create a mature global eco-system to speed up timely diagnosis, generate knowledge, to strengthen health systems locally.

This Thought-Leader Session will explore how healthcare systems in the WHO European region could connect into a Global Network, building on and scaling up the ERN system, exploiting the digitalisation of healthcare and harnessing the collective knowledge from the existing networks to unify an international expert community.

Agenda: Timing CEST

17.00: Introductions & setting the scene Ines Hernando, EURORDIS

17.05: Concept Model for the Global Network for Rare Diseases Matt

Bolz-Johnson, Rare Diseases International

17.15: EURO Region Readiness

Michelle Battye, ERN eUROGEN

17.25 : Patient Perspective Salman Saif, Cure4U (TBC)

17.35: Panel Discussion & Q&A

17.55: Closing Remarks
Ines Hernando, EURORDIS

Thought Leader Session 3

Rare Diseases (RD) Partnership (Horizon Europe)-Ambition, Vision and Mission Chaired by Daria Julkowska, European Programme on Rare Diseases

Join us to discover the ambition, vision and mission of the future Rare Diseases (RD) Partnership under the Horizon Europe programme and get answers to your questions!

The aim of the Rare Diseases (RD) Partnership is to improve the health and well-being of 30 million persons living with a rare disease in Europe, by making Europe a world leader in RD research and innovation and delivering concrete health benefits to rare disease patients through better prevention, diagnosis and treatments.

To leave no one behind, RD Partnership will deliver a RD multi-stakeholder ecosystem by supporting robust patient-need-led research, developing new therapies and diagnostic pathways, by utilizing the power of health and research data and spearheading the digital transformational change in RD research and innovation (R&I).

The Partnership will structure the European Research Area (ERA) on RD by supporting the coordination and alignment of national and regional research strategies, including the establishment of public-private collaborations, through research activities all along the R&I value chain, ensuring that the journey from knowledge to patient impact is expedited, thereby optimising EU innovation potential in RD.

Join Daria and other RD leaders to find out more during this interactive session designed for all stakeholders in the rare disease community.